Israeli researchers were part of a global study that discovered a link between anomalies in gut microbes and autism that could provide new treatment options for individuals with Autism Spectrum Disorder.
Researchers from the Azrieli Faculty of Medicine at Bar-Ilan University partnered with the Israel Registry and Biobank of Autism (IRBA) in the study of gut microbiomes (the trillions of microbes that colonize your gut) in 48 neurotypical and 48 autistic children from around the world.
The study, which was published by the Nature Neuroscience journal, showed more than 2,000 differences in the genes between both groups, suggesting that microbiome-based therapeutic interventions could help to treat individuals with autism.
The researchers say that this personalized approach holds the potential to significantly improve outcomes and quality of life for those on the autism spectrum, and plan to expand their research with IRBA.
Gut microbiomes regulate your gut-brain axis (GBA), which connects the emotional and cognitive centers of the brain with intestinal functions, and disruptions of the gut microbiome are thought to contribute to ASD or other neurodevelopmental disorders. ASD affects about 75 million people worldwide, according to the US Centers for Disease Control and Prevention.
“Our collaborative study presents a significant breakthrough, revealing the profound influence of the gut-brain axis on the biology of autism,” said Prof. Evan Elliott of Bar-Ilan University, a key researcher in the study.
“The correlation between microbiome alterations and immune system markers provides valuable insights into how the gut microbiome may influence the health of individuals diagnosed with autism,” he said.
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors

Ashdod Port Investing In Startups As Part Of Innovation Strategy

Facebook comments